140 related articles for article (PubMed ID: 21757225)
1. PPARγ activation induces acute PAI-1 gene expression in the liver but not in adipose tissues of diabetic model mice.
Oishi K; Tomita T; Itoh N; Ohkura N
Thromb Res; 2011 Nov; 128(5):e81-5. PubMed ID: 21757225
[TBL] [Abstract][Full Text] [Related]
2. Adiponectin mediates the suppressive effect of rosiglitazone on plasminogen activator inhibitor-1 production.
Hoo RL; Chow WS; Yau MH; Xu A; Tso AW; Tse HF; Fong CH; Tam S; Chan L; Lam KS
Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2777-82. PubMed ID: 17932317
[TBL] [Abstract][Full Text] [Related]
3. Food deprivation induces adipose plasminogen activator inhibitor-1 (PAI-1) expression without accumulation of plasma PAI-1 in genetically obese and diabetic db/db mice.
Oishi K; Ohkura N; Matsuda J; Ishida N
Thromb Haemost; 2007 Oct; 98(4):864-70. PubMed ID: 17938813
[TBL] [Abstract][Full Text] [Related]
4. PPARα deficiency augments a ketogenic diet-induced circadian PAI-1 expression possibly through PPARγ activation in the liver.
Oishi K; Uchida D; Ohkura N; Horie S
Biochem Biophys Res Commun; 2010 Oct; 401(2):313-8. PubMed ID: 20854792
[TBL] [Abstract][Full Text] [Related]
5. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
[TBL] [Abstract][Full Text] [Related]
6. Rosiglitazone prevents advanced glycation end products-induced renal toxicity likely through suppression of plasminogen activator inhibitor-1.
Yu X; Li C; Li X; Cai L
Toxicol Sci; 2007 Apr; 96(2):346-56. PubMed ID: 17264099
[TBL] [Abstract][Full Text] [Related]
7. Pioglitazone suppresses advanced glycation end product-induced expression of plasminogen activator inhibitor-1 in vascular smooth muscle cells.
Yuan X; Liu N
J Genet Genomics; 2011 May; 38(5):193-200. PubMed ID: 21621740
[TBL] [Abstract][Full Text] [Related]
8. The PPARgamma ligand, rosiglitazone, reduces vascular oxidative stress and NADPH oxidase expression in diabetic mice.
Hwang J; Kleinhenz DJ; Rupnow HL; Campbell AG; Thulé PM; Sutliff RL; Hart CM
Vascul Pharmacol; 2007 Jun; 46(6):456-62. PubMed ID: 17337254
[TBL] [Abstract][Full Text] [Related]
9. Insulin and oleic acid increase PPARgamma2 expression in cultured mouse hepatocytes.
Edvardsson U; Ljungberg A; Oscarsson J
Biochem Biophys Res Commun; 2006 Feb; 340(1):111-7. PubMed ID: 16364246
[TBL] [Abstract][Full Text] [Related]
10. Blood glucose-lowering nuclear receptor agonists only partially normalize hepatic gene expression in db/db mice.
Loffler M; Bilban M; Reimers M; Waldhäusl W; Stulnig TM
J Pharmacol Exp Ther; 2006 Feb; 316(2):797-804. PubMed ID: 16260581
[TBL] [Abstract][Full Text] [Related]
11. Thiazolidinediones inhibit TNFalpha induction of PAI-1 independent of PPARgamma activation.
Liu HB; Hu YS; Medcalf RL; Simpson RW; Dear AE
Biochem Biophys Res Commun; 2005 Aug; 334(1):30-7. PubMed ID: 15990085
[TBL] [Abstract][Full Text] [Related]
12. Cilostazol ameliorates metabolic abnormalities with suppression of proinflammatory markers in a db/db mouse model of type 2 diabetes via activation of peroxisome proliferator-activated receptor gamma transcription.
Park SY; Shin HK; Lee JH; Kim CD; Lee WS; Rhim BY; Hong KW
J Pharmacol Exp Ther; 2009 May; 329(2):571-9. PubMed ID: 19221061
[TBL] [Abstract][Full Text] [Related]
13. Impact of statins on modulation by insulin of expression of plasminogen activator inhibitor type-1.
Sato Y; Dong J; Imagawa S; Ishimori N; Furumoto T; Tsutsui H; Sobel BE; Fujii S
Coron Artery Dis; 2008 Aug; 19(5):355-61. PubMed ID: 18607173
[TBL] [Abstract][Full Text] [Related]
14. Adverse hepatic and cardiac responses to rosiglitazone in a new mouse model of type 2 diabetes: relation to dysregulated phosphatidylcholine metabolism.
Pan HJ; Lin Y; Chen YE; Vance DE; Leiter EH
Vascul Pharmacol; 2006 Jul; 45(1):65-71. PubMed ID: 16750656
[TBL] [Abstract][Full Text] [Related]
15. Tumor necrosis factor-alpha-induced production of plasminogen activator inhibitor 1 and its regulation by pioglitazone and cerivastatin in a nonmalignant human hepatocyte cell line.
Takeshita Y; Takamura T; Hamaguchi E; Shimizu A; Ota T; Sakurai M; Kaneko S
Metabolism; 2006 Nov; 55(11):1464-72. PubMed ID: 17046548
[TBL] [Abstract][Full Text] [Related]
16. Keratinocyte-derived vascular endothelial growth factor biosynthesis represents a pleiotropic side effect of peroxisome proliferator-activated receptor-gamma agonist troglitazone but not rosiglitazone and involves activation of p38 mitogen-activated protein kinase: implications for diabetes-impaired skin repair.
Schiefelbein D; Seitz O; Goren I; Dissmann JP; Schmidt H; Bachmann M; Sader R; Geisslinger G; Pfeilschifter J; Frank S
Mol Pharmacol; 2008 Oct; 74(4):952-63. PubMed ID: 18599600
[TBL] [Abstract][Full Text] [Related]
17. Metformin, but not thiazolidinediones, inhibits plasminogen activator inhibitor-1 production in human adipose tissue in vitro.
He G; Pedersen SB; Bruun JM; Lihn AS; Richelsen B
Horm Metab Res; 2003 Jan; 35(1):18-23. PubMed ID: 12669266
[TBL] [Abstract][Full Text] [Related]
18. Plasminogen activator inhibitor-1 modulates adipocyte differentiation.
Liang X; Kanjanabuch T; Mao SL; Hao CM; Tang YW; Declerck PJ; Hasty AH; Wasserman DH; Fogo AB; Ma LJ
Am J Physiol Endocrinol Metab; 2006 Jan; 290(1):E103-E113. PubMed ID: 16144810
[TBL] [Abstract][Full Text] [Related]
19. Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone.
Larsen PJ; Lykkegaard K; Larsen LK; Fleckner J; Sauerberg P; Wassermann K; Wulff EM
Eur J Pharmacol; 2008 Oct; 596(1-3):173-9. PubMed ID: 18761337
[TBL] [Abstract][Full Text] [Related]
20. Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones.
Zirlik A; Leugers A; Lohrmann J; Ernst S; Sobel BE; Bode C; Nordt TK
Thromb Haemost; 2004 Apr; 91(4):674-82. PubMed ID: 15045127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
